BioNTech confirmed that co‑founders Ugur Şahin and Özlem Türeci will step down by year‑end to found a new company focused on next‑generation mRNA technologies. BioNTech said it will grant the new venture certain mRNA rights and take a minority stake, while it concentrates on advancing a late‑stage oncology portfolio. The founders’ departure coincides with BioNTech’s shift to multiple late‑stage cancer programs and a planned expansion of Phase III oncology trials. The company said the transition will be managed to ensure continuity for ongoing pivotal programs and collaborations.